Novel biological strategies in inflammatory bowel diseases.
Vermeire
Severine
S
Department of Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
Rutgeerts
Paul
P
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001691:Biological Therapy / Q000379:methods*; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors; D016207:Cytokines / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000628:therapy*; D011355:Prodrugs / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D015815:Cell Adhesion Molecules; D016207:Cytokines; D007166:Immunosuppressive Agents; D011355:Prodrugs; D014409:Tumor Necrosis Factor-alpha